Compare TBPH & BTQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | BTQ |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 929.8M |
| IPO Year | N/A | N/A |
| Metric | TBPH | BTQ |
|---|---|---|
| Price | $18.67 | $5.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $27.80 | $10.00 |
| AVG Volume (30 Days) | 528.0K | ★ 3.1M |
| Earning Date | 11-10-2025 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $80,327,000.00 | $405,988.00 |
| Revenue This Year | $70.78 | $100.70 |
| Revenue Next Year | N/A | $669.96 |
| P/E Ratio | $32.28 | ★ N/A |
| Revenue Growth | 27.12 | ★ 35.72 |
| 52 Week Low | $7.90 | $0.95 |
| 52 Week High | $20.33 | $16.00 |
| Indicator | TBPH | BTQ |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | N/A |
| Support Level | $17.25 | N/A |
| Resistance Level | $19.13 | N/A |
| Average True Range (ATR) | 0.65 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 78.72 | 0.00 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. Its products include PQScale, Keelung, Kenting, and Qbyte. PQScale is a novel scaling technique for post-quantum cryptographic primitives. Keelung is a zero-knowledge toolkit for fast, private, and secure applications. Kenting provides acceleration for NIST-compliant post-quantum cryptography, post-quantum zk-SNARKs, and eco-friendly mining hardware, and Qbyte is a quantum risk calculator. Geographically, the company derives maximum revenue from Canada, and also has a presence in Taiwan, and Australia.